Search Medical Condition
Please enter condition
Please choose location from dropdown

Giessen, Germany Clinical Trials

A listing of Giessen, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (101) clinical trials

Phase 2b Study to Evaluate the Efficacy and Safety of GBR 830 in Adults With Moderate to Severe Atopic Dermatitis

Phase 2b, randomized, double-blinded, placebo-controlled dose range finding study to evaluate the efficacy, safety and tolerability of GBR 830 in adults with moderate to severe atopic dermatitis.

Phase

0.2 miles

Learn More »

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera )

This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera).

Phase

0.75 miles

Learn More »

Observation Combination Chemotherapy Radiation Therapy and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

OBJECTIVES: Primary - Determine the event-free survival (EFS) of younger patients with newly diagnosed neuroblastoma categorized in the low-risk group (LRG) who undergo observation only or receive combination chemotherapy. - Compare the EFS rate in patients with neuroblastoma categorized in the medium-risk group (MRG) treated with combination induction therapy, maintenance ...

Phase

0.75 miles

Learn More »

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

In a group of young stroke patients with diagnosed Fabry disease the stroke rehabilitation will be investigated during different prophylactic therapeutic approaches. In this study the investigator will not be given any instructions on stroke and Fabry therapy. All patients with any etiology of stroke and a diagnosed Fabry disease ...

Phase N/A

0.75 miles

Learn More »

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

OBJECTIVES: Primary - Compare the event-free survival of pediatric patients with high-risk neuroblastoma treated with standard induction chemotherapy vs topotecan hydrochloride-containing induction chemotherapy followed by myeloablative autologous stem cell transplantation and consolidation therapy with isotretinoin. Secondary - Compare the overall survival of patients treated with these regimens. - Compare early ...

Phase N/A

0.75 miles

Learn More »

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor

Study design. This academic investigator - initiated trial will resolve the key issue whether, and if yes, to what extent and variability, the treatment with lumacaftor in combination with ivacaftor (Orkambi) will reverse the p.Phe508del CFTR - mediated basic defect in p.Phe508del homozygous subjects with cystic fibrosis under real life ...

Phase N/A

0.75 miles

Learn More »

Surgery Alone Surgery With Cyclophosphamide Vinblastine and Prednisolone (CVP) or CVP Alone in Treating Young Patients With Stage IA or Stage IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma

OBJECTIVES Primary Determine the 5-year event-free survival of children or adolescents with stage IA or IIA nodular lymphocyte-predominant Hodgkin lymphoma treated with surgery alone or with cyclophosphamide, vinblastine, and prednisolone. Secondary Determine if this regimen results in a decrease in overall survival rates, in significant upstaging at relapse, or increased ...

Phase

0.75 miles

Learn More »

BAROSTIM THERAPY in Heart Failure With Reduced Ejection Fraction

The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).

Phase N/A

1.05 miles

Learn More »

BAROSTIM THERAPY In Resistant Hypertension

The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.

Phase N/A

1.05 miles

Learn More »

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old With Hodgkin's Lymphoma (cHL) Relapsed or Refractory From First Line Treatment

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.

Phase

1.05 miles

Learn More »